Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease

被引：29

作者：

Bannai, Ei ^{[1
]}

Yamashita, Hiroyuki ^{[1
]}

Kaneko, Shunta ^{[1
]}

Ueda, Yo ^{[1
]}

Ozaki, Takashi ^{[1
]}

Tsuchiya, Haruka ^{[1
]}

Takahashi, Yuko ^{[1
]}

Kaneko, Hiroshi ^{[1
]}

Kano, Toshikazu ^{[1
]}

Mimori, Akio ^{[1
]}

机构：

[1] Natl Ctr Global Hlth & Med, Div Rheumat Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan

来源：

MODERN RHEUMATOLOGY | 2016年 / 26卷 / 02期

关键词：

Adult-onset Still's disease; Tocilizumab; Macrophage activation syndrome; MACROPHAGE ACTIVATION SYNDROME; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; RECEPTOR ANTIBODY; IL-6; RECEPTOR; EFFICACY; INTERLEUKIN-6; AGENTS; TRIAL;

D O I：

10.3109/14397595.2014.899178

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To evaluate the effects of tocilizumab (TCZ) on adult-onset Still's disease (AOSD), we reviewed medical records of seven patients with refractory AOSD treated with TCZ at our institution. TCZ therapy might allow rapid corticosteroid tapering and help maintain remission status, that is, resolution of clinical symptoms and normalization of biomarkers such as CRP and ferritin. Patients, however, should be monitored for the development of macrophage activation syndrome when TCZ is administered for active AOSD.

引用

页码：297 / 301

页数：5

共 50 条

[21] A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature
Perdan-Pirkmajer, Katja
Praprotnik, Sonja
Tomsic, Matija
CLINICAL RHEUMATOLOGY, 2010, 29 (12) : 1465 - 1467
[22] PILOT TRIAL OF TOCILIZUMAB FOR REFRACTORY PATIENTS WITH ADULT ONSET STILL'S DISEASE
Kim, J. J.
Na, K. S.
Kim, T. H.
Yoo, D. H.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 322 - 322
[23] Publisher Correction: A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
Ting Li
Liyang Gu
Xiaodong Wang
Li Guo
Hui Shi
Chengde Yang
Sheng Chen
Scientific Reports, 8
[24] Refractory urticaria in adult-onset Still's disease
Tseng, Han-Chi
Lee, Chih-Hung
RHEUMATOLOGY INTERNATIONAL, 2014, 34 (07) : 1029 - 1030
[25] Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still's Disease
Sun, Ziyi
Li, Rongqi
Wang, Yingai
Han, Feng
Wei, Wei
Li, Xin
DRUGS IN R&D, 2023, 23 (02) : 109 - 120
[26] Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
Ziyi Sun
Rongqi Li
Yingai Wang
Feng Han
Wei Wei
Xin Li
Drugs in R&D, 2023, 23 : 109 - 120
[27] Successful treatment of a patient with refractory adult-onset still disease with anakinra
Rudinskaya, A
Trock, DH
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2003, 9 (05) : 330 - 332
[28] Tocilizumab discontinuation after remission achievement in patients with adult-onset Still's disease
Tamai, Hiroya
Kondo, Yasushi
Takeuchi, Tsutomu
Kaneko, Yuko
RHEUMATOLOGY, 2024,
[29] Adult-onset Still?s Disease during Pregnancy Treated with Tocilizumab
Imaizumi, Chihiro
Saito, Masaya
Abe, Fumito
Kaga, Hajime
Saito, Ayano
Nara, Mizuho
Kameyama, Saeko
Miura, Hiroshi
Ogasawara, Hitoshi
Hirakawa, Takeo
Mizunuma, Makito
Satoh, Makiko
Komatsuda, Atsushi
Terada, Yukihiro
Takahashi, Naoto
INTERNAL MEDICINE, 2022, 61 (20) : 3137 - 3140
[30] Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab
Yamada, Hiroki
Kaneko, Yuko
Tamai, Hiroya
Takeuchi, Tsutomu
RHEUMATOLOGY, 2020, 59 (02) : 440 - 442

← 1 2 3 4 5 →